Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  topotecan hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 44 for your search:
Start Over
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00629, GOG-0281, U10CA180868, U10CA027469, NCT02101788
Hydralazine Valproate for Cervical Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 006/027/ICI, NCT00532818
Hydralazine Valproate for Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 006/028/DDI, NCT00533299
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 50 and under
Sponsor: NCI, Other
Protocol IDs: AEWS1031, NCI-2011-02611, COG-AEWS1031, CDR0000687639, U10CA098543, NCT01231906
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 17 months and under
Sponsor: NCI, Other
Protocol IDs: ANBL1232, NCI-2014-00677, U10CA098543, U10CA180886, NCT02176967
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-C-004-14, NCT02421588
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PazTo_2010, NCT01600573
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ME-344-002, NCT02100007
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: 1000046233, IND.217, NCT02303028
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCI 03-33, NCT00257816
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: V0706, NCT00601003
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AMLSG-R1, NCT00744081
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 20
Sponsor: Other
Protocol IDs: MIITOP-0607, COL-MIITOP, MIITOP, COL-2006-07, INCA-RECF0633, EUDRACT-2006-004862-15, NCT00960739
Study of Cisplatin in Cervical Cancer Stage IVB
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CACA-2008-GSK1, NCT00826891
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SNUCH-SCT-1102, NCT01342237
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSOM230DUS21T, NCT01417806
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: 11-183, NCT01492673
Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11SCLC09I, NCT01497873
Efficacy and Safety of Belotecan or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11AOC09J, NCT01630018
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 76
Sponsor: Other
Protocol IDs: CNIO-GI-01-2012, NCT01703910
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18 to 79
Sponsor: Other
Protocol IDs: P05200, NCT01736800
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-1726, NCI-2013-00402, NCT01803269
Therapy for Children With Advanced Stage Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 19
Sponsor: Other
Protocol IDs: NB2012, NCI-2013-00034, NCT01857934
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: SJATRT, NCI-2014-00901, NCT02114229
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALDOXORUBICIN-P2-SCLC-01, NCT02200757
Start Over